Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05239975 Withdrawn - COVID-19 Clinical Trials

A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

Start date: April 25, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥12 years and previously fully immunized with inactivated COVID-19 vaccine.

NCT ID: NCT05239923 Completed - COVID-19 Pneumonia Clinical Trials

COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

Start date: August 28, 2021
Phase: N/A
Study type: Interventional

This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.

NCT ID: NCT05239832 Active, not recruiting - COVID-19 Pandemic Clinical Trials

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

COVID-19
Start date: August 5, 2021
Phase: Phase 2
Study type: Interventional

A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

NCT ID: NCT05239806 Not yet recruiting - COVID-19 Clinical Trials

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster. The study will also evaluate the immunogenicity and safety of 2-dose vaccinations.

NCT ID: NCT05239598 Completed - COVID-19 Clinical Trials

Povidone-Iodine Oral Rinse Study

Start date: February 7, 2022
Phase: Phase 2
Study type: Interventional

This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals. Phase II is designed as an open label trial, and all subjects will receive the active mouthwash.

NCT ID: NCT05238649 Active, not recruiting - COVID-19 Pandemic Clinical Trials

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

COVID-19
Start date: November 10, 2021
Phase: Phase 2
Study type: Interventional

A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

NCT ID: NCT05238623 Active, not recruiting - COVID-19 Pneumonia Clinical Trials

Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19

Start date: March 1, 2022
Phase:
Study type: Observational

Investigation of the correlation of CT-morphological changes of the lung compared to regional ventilation distribution on electrical impedance tomography in patients with post-acute-Covid-19 symptoms.

NCT ID: NCT05238454 Not yet recruiting - COVID-19 Clinical Trials

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

Start date: March 20, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with COVID-19.

NCT ID: NCT05238441 Not yet recruiting - COVID-19 Clinical Trials

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Start date: March 20, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.

NCT ID: NCT05238428 Completed - Vaccine Refusal Clinical Trials

Understanding and Overcoming the Racial/Ethnic Inequalities in COVID-19 Vaccination Acceptance

Start date: February 3, 2022
Phase: N/A
Study type: Interventional

With the constant threat of new epidemic waves and the emergence of variants, COVID-19 resilience can only be attained when a sufficient level of immunity is achieved. Yet, in the US and the UK, COVID-19 vaccination campaigns have failed to secure consistent vaccination acceptance in racial/ethnic minority communities. Despite racial/ethnic minorities being more at risk from COVID-19, they are less vaccinated than the White majority. The investigators propose that current vaccination invitation messages are deemed less trustworthy by racial/ethnic minorities than the White majority and that this might partly explain reduced vaccination acceptance. To provide causal evidence of the role of trust and actionable insights, the investigators will experimentally assess the benefits of new invitation messages to receive the COVID-19 booster dose in large, racially/ethnically diverse samples in the US and the UK. Results will evidence how to increase message and source trustworthiness to foster trust and vaccination acceptance across racial/ethnic groups.